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Summary A fatal case of Scopulariopsis acremonium sinus infection in an allogeneic hema-
topoietic stem cell transplant patient is reported. Rapid vascular diffusion of the fungus to the
major head vessels was observed, which led to subsequent repeated cerebral ischemia and death.
The presence of hyphae in the right carotid wall might be considered an indirect sign of fungal
blood diffusion in the absence of positive blood cultures. The infection developed during the
course of prolonged voriconazole prophylaxis, which was found to be effective in the in vitro
antifungal drug assay. This finding induced us to consider the capacity of this drug to reach
infected paranasal sinuses, and the need in cases such as this of a combined systemic and local
pharmacological therapy or a combined medical and surgical approach.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Invasive fungal sinusitis is a potentially fatal disease that
typically affects immunocompromised patients, such as
those receiving intensive chemotherapy or undergoing an
allogeneic hematopoietic stem cell transplantation
(HSCT).1—4 A wide range of causative pathogens has been
described, with Aspergillus and Mucor remaining the most* Corresponding author. Tel.: +39 0 6 20903343;
fax: +39 0 6 72596873.
E-mail address: sarmati@med.uniroma2.it (L. Sarmati).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.01.020common agents.3,5 The mortality as a result of this clinical
entity varies depending on the underlying disease, site of
infection, and antifungal management, and it remains very
high — up to 60% by some estimates.3,4 A late diagnosis often
results in vascular invasion and spread of the infection to
contiguous tissues, so worsening the prognosis and increasing
the mortality.
Scopulariopsis spp are nondermatophytic fungi, cosmopo-
lite and common soil saprophytes. Scopulariopsis brevicaulis
is most frequently isolated in immunocompetent patients
with onychomycosis and localized infections and is rarely
reported as a causative agent of disseminated infection inPublished by Elsevier Ltd. All rights reserved.
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iopsis acremonium has only been described in two immuno-
compromised patients.
We report herein a rare case of invasive fungal sinusitis
caused by S. acremonium in a bone marrow transplant
patient, which developed during antifungal prophylaxis with
voriconazole.
Case report
In January 2005, a 50-year-old woman, originally from Cape
Verde, but resident in Italy for approximately 10 years,
received the diagnosis of IgG kappa, stage IIA multiple mye-
loma (total tumor burden 0.6—1.2  1012 cells/m2, serum
creatinine <2 mg/dl, or intermediate stage according to the
Durie and Salmon staging system).12
From January to April 2005 she underwent four courses of
combined chemotherapy and dexamethasone with subse-
quent partial remission of the disease. In May 2005, after
mobilization induced by cyclophosphamide and granulocyte
colony-stimulating factor (G-CSF), CD34+ cells (2.26  106/
kg) were collected from her peripheral blood. In August 2005,
the patient underwent to an autologous stem cell transplant.
In March 2006, she was admitted to the Hematology Stem
Cell Transplant Unit and an allogeneic HSCT from her humanFigure 1 Magnetic resonance images showing evidence of mucoleukocyte antigen (HLA)-identical brother was performed. As
a conditioning regimen, she received a myeloablative regi-
men combining busulfan and fludarabine, and cyclosporine
with methotrexate was used as prophylaxis against graft-
versus-host disease (GVHD). The patient was discharged at
day 17 after transplant in a good condition and in complete
illness remission, with normal hematopoietic reconstitution
of full donor origin. Prior to the transplant, a magnetic
resonance image (MRI) of the paranasal sinuses showed a
mucosal thickening of the left maxillary sinus, with polypoid
formations.
In July 2006, the patient was readmitted to the Hematol-
ogy Stem Cell Transplant Unit for biopsy-proven acute intest-
inal GVHD (Lerner grade III—IV), and treated with prednisone
(2 mg/kg/day) and cyclosporine (3 mg/kg/day). During this
hospitalization, due to the appearance of sinusitis and a
suspicion of fungal disease, liposomal amphotericin B
(3 mg/kg/day) was given for 21 days, followed by voricona-
zole (200 mg orally, every 12 hours) as antifungal secondary
prophylaxis. No microbiological results were obtained from
sinus swab cultures on this occasion.
In August 2007 (485 days after transplant) she was
admitted to the hospital with acute blindness and edema
of the right eyelid. She was on prednisone and mycopheno-
late mofetil for chronic intestinal GVHD, and was still onsal thickening of the ethmoidal (A—C) and frontal (D) sinuses.
Table 1 Antifungal susceptibility of the Scopulariopsis acre-
monium isolate
Antifungal drug MIC (mg/ml)
Amphotericin B 2
Posaconazole 0.5
Fluconazole 256
Itraconazole 16
Ketoconazole 2
5-Flucytosine 64
Voriconazole 2
Caspofungin 1
MIC, minimum inhibitory concentration.
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frontal sinusitis (Figure 1), and an ocular fundus evaluation
revealed an ischemia of the right retinal artery. Voriconazole
was stopped and treatment with liposomal amphotericin B
(3 mg/kg) and piperacillin/tazobactam was begun.
After 10 days of treatment, the patient developed com-
plete left-sided hemiplegia, and a computed tomography
(CT) scan showed a large cerebral ischemia of the right
temporal area (Figure 2).
Fourteen days after admission, a culture from the sinus
secretion grew Scopulariopsis acremonium. Susceptibility
testing of the isolate was performed according to the
broth microdilution method.13,14 The minimum inhibitory
concentrations (MICs) were determined using the reference
procedure of the Antifungal Susceptibility Testing Subcom-
mittee of the European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) for spore-forming molds.15
Amphotericin B, fluconazole, and itraconazole were found
to be inactive in vitro against the isolate; however it was
found to be sensitive to voriconazole (Table 1). As the
infection developed during voriconazole prophylaxis, treat-
ment with echinocandins (caspofungin) was started, but the
patient died two days later due to a new episode of brain
ischemia and hemorrhage.
Autopsy revealed the presence of thrombosis of the right
carotid artery and of the middle cerebral artery, with the
consistent presence of fungal filamentous hyphae in theFigure 2 Axial computed tomography scan showingvessel walls (Figure 3). Necrotic material and a polymorpho-
nuclear infiltrate were found in the sinuses (Figure 4). The
autopsy concluded that death was as a result of a septic
embolism from sinus to arterial circulation, caused by Sco-
pulariopsis acremonium.
Discussion
Infections due to infrequently encountered fungi (e.g., hya-
line molds, dematiaceous filamentous fungi, and zygomy-
cetes) have become increasingly common in hematopoieticlarge right hemispherical brain ischemia (A—C).
Figure 3 The carotid artery wall with evidence of thin, septate hyphae (Gomori methenamine silver stain; magnification (A) 4, (B)
40).
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opportunistic molds are often refractory to conventional
antifungal agents and have innate resistance or erratic sus-
ceptibility to amphotericin B. All these factors account for
the very low one-year survival (about 20%) of HSCTrecipients
with invasive mold infections.16
Mold infections are frequently disseminated to numerous
other organs and tissues, and this is probably related to in
vivo sporulation and the production of adventitious forms
(hyphae, phialides, and phialoconidia) with a rapid vascular
spread.18 This suggested mechanism for the dissemination of
infection could confer a particular virulence and resistance
to treatment of these kinds of fungi.
Only two cases of infection by S. acremonium have been
reported in the literature, one in a leukemic patient and one
in a lung transplant patient.11,19 The transplant patient had
a fatal disseminated infection, while the leukemic patient
had a sinusitis that was successfully treated with a combina-
tion of medical (amphotericin B plus itraconazole) and
surgical (endoscopic sinus surgery) methods. In neither of
the two cases was a hematogenous spread of the infection
documented.Figure 4 Fragment of the frontal sinus: evidence of bone
necrosis and polymorphonuclear infiltrate (magnification 10).The clinical picture in our case was suggestive of a rapid
vascular diffusion, with early involvement of the retinal
artery and diffusion to the major head arteries. We had no
positive blood culture; however, the presence of hyphal
forms in the wall of the carotid could be considered a sign
of vascular spread of the pathogen. The rapid vascular
diffusion negatively influenced the clinical course in our
patient.
The S. acremonium isolated in our case was found to be
resistant to a large number of antimycotic drugs, and in
particular to amphotericin B. There is a paucity of data
regarding the in vitro antifungal susceptibility of Scopular-
iopsis spp;13,20,21 however, a large number of clinical and
environmental isolates have demonstrated a broad spectrum
of resistance against antifungal agents.21 Our patient devel-
oped S. acremonium infection while on prophylaxis with
voriconazole, which in contrast to the other azole agents,
was found to be effective in vitro. This finding could be
explained by the possible limited diffusion of oral voricona-
zole or by insufficient penetration of the drug into the
sinuses.
In conclusion, S. acremonium infection in HSCT patients is
rare but can be a dramatic event due to the natural reduced
sensitivity of the pathogen to antifungal drugs and its poten-
tial to spread rapidly by blood diffusion. Nasal sinuses as the
site of infection make rapid diagnosis and treatment more
difficult. Results of this study have led us to consider the use
of combined systemic and local antifungal treatment and to
evaluate the timing of a surgical approach in this kind of
fungal infection, as has also been suggested by other
authors.22
Early diagnostic procedures such as biopsy, or at the least
endoscopic cultures, should be performed prior to starting
empirical antifungal treatment in order to improve the out-
come of this disease in the immunocompromised host.
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